Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics

• Main Authors: Chris Chun-Yiu Chan (Author), Qian Guo (Author), Jasper Fuk-Woo Chan (Author), Kaiming Tang (Author), Jian-Piao Cai (Author), Kenn Ka-Heng Chik (Author), Yixin Huang (Author), Mei Dai (Author), Bo Qin (Author), Chon Phin Ong (Author), Allen Wing-Ho Chu (Author), Wan-Mui Chan (Author), Jonathan Daniel Ip (Author), Lei Wen (Author), Jessica Oi-Ling Tsang (Author), Tong-Yun Wang (Author), Yubin Xie (Author), Zhenzhi Qin (Author), Jianli Cao (Author), Zi-Wei Ye (Author), Hin Chu (Author), Kelvin Kai-Wang To (Author), Xing-Yi Ge (Author), Tao Ni (Author), Dong-Yan Jin (Author), Sheng Cui (Author), Kwok-Yung Yuen (Author), Shuofeng Yuan (Author)
• Format: Book
• Published: Elsevier, 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

There are only eight approved small molecule antiviral drugs for treating COVID-19. Among them, four are nucleotide analogues (remdesivir, JT001, molnupiravir, and azvudine), while the other four are protease inhibitors (nirmatrelvir, ensitrelvir, leritrelvir, and simnotrelvir-ritonavir). Antiviral...